pharma · Chronic Lymphocytic Leukemia (CLL) · Relapsed/Refractory B-cell Malignancies · NRIX
Nurix Therapeutics
Nurix Therapeutics is a pharma organization headquartered in Brisbane, USA. It trades on NYSE under ticker NRIX. Primary therapeutic focus areas include Chronic Lymphocytic Leukemia (CLL), Relapsed/Refractory B-cell Mali
Brisbane, USA HQ
2012 Founded
350 Employees
Public company Type
NRIX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Brisbane, USA
- Founded
- 2012
- Employees
- 350
- Programs
- 9
- Drugs
- 4
- Patents
- 14
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 · other · Relapsed/Refractory B-cell Malignancies
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies for Relapsed/Refractory B-cell Malignancies is a Phase 1 program (other) at Nurix Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code NX-5948-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Nurix Therapeutics
- Phase
- Phase 1
- Modality
- other
- Indication
- Relapsed/Refractory B-cell Malignancies
- Status
- active
- Trials
- 1